Respiratory Virus Infection Drugs Market
Respiratory Virus Infection Drugs Market (Drug Type: Antibiotics, Non-Steroidal Anti-Inflammatory Drugs [NSAIDS], Cough Suppressants, Nasal Decongestants, and Others; Infection Type: Respiratory Syncytial Virus [RSV] Infection, Influenza Virus Infection, Parainfluenza Virus Infection, Adenovirus Infection, Rhinovirus Infection, and Others; Route of Administration: Oral and Parenteral; Mode of Purchase: Prescription-based Drugs and Over-the-counter Drugs; and Distribution Channel: Hospital Pharmacies, Drug Stores, Retail Pharmacies, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030
Press Release :
Intelligent AI, ML Algorithms Supporting COVID-19 Molecular Applications
The AI (Artificial Intelligence)-driven COVID-19 drug discovery is gaining increased popularity in the respiratory virus infection drugs market. Since the coronavirus has become an international health concern, there has been an unprecedented demand for drugs and vaccines. As such, AI holds promising potentials in quick identification of COVID-19 drugs. Thus, companies in the respiratory virus infection drugs market are collaborating with scientists and researchers to predict drugs and peptides that can be used as therapeutic medication for coronavirus treatment.
Pharmaceutical companies are increasing efforts to predict drugs directly from the sequences of infected patients, since they have a better affinity with the target. However, companies need to accelerate their testing capabilities in order to verify safety and feasibility to combat COVID-19. Intelligent algorithms based on machine learning (ML) and Big Data are supporting molecular applications.
To know the scope of our report Get a Sample on Respiratory Virus Infection Drugs Market
Rise in R&D Helps Address Low Solubility of Favipiravir in Aqueous Media
The respiratory virus infection drugs market is expected to surpass a value of US$ 82.4 Bn by the end of 2030. However, individuals are becoming increasingly aware about the disadvantages and side effects of influenza drugs, namely favipiravir and baloxavir. Pharma companies need to address low solubility of favipiravir in aqueous media, which may reduce its efficacy in vitro. This indicates that pharma companies need to increase their R&D activities to prevent adverse events of drugs.
Pharma companies are focusing on discoveries in influenza virus polymerase complex. It has been found that influenza viruses are severe human pathogens that pose as a persistent threat to public health. Hence, companies in the respiratory virus infection drugs market are capitalizing on this issue to increase their R&D in influenza virus polymerase complex.
Get a glimpse of the in-depth analysis through our Report Brochure
Efficient Drug Delivery via Nanotechnology Offers Growth Prospects in Clinical Practice
Companies in the respiratory virus infection drugs market are increasing their focus in nanomaterials designed for antiviral drug delivery of adenovirus infection. This has become important, since respiratory virus infections have become a global health problem causing a significant amount of mortality and morbidity in individuals. Emerging drug resistance and constant viral replication have led to the demand for nanotechnology in antiviral therapies, as nanomaterials offer unique physic-chemical properties ideal for the treatment of adenovirus infection.
Different nanomaterials such as nanosheres, liposomes, nanoparticles, nanogels, and the likes hold promising potentials for efficacious drug administration in order to improve patient outcomes. Companies in the respiratory virus infection drugs market are innovating in nanosuspensions and nanoemulsions to enable drug delivery of unique antiviral agents with prospects in clinical practice.
AI-based Multi-program Approach Enables Development of Successful Candidates for Antibiotic Resistance
The COVID-19 pandemic has brought startups in the respiratory virus infection drugs market under great emphasis. For instance, Vir Biotechnology— a specialist in immune therapeutics, is leveraging the advantages of AI and ML in influenza drug development. It has been found that infectious diseases have increased resistance to antibiotics. Startups in the respiratory virus infection drugs market are capitalizing on this opportunity to integrate AI and ML in common cold and influenza drug development.
In order to broaden their revenue streams, the U.S.-based tech startups are working on solutions to address antibiotic resistance in certain strains of influenza A, SARS-CoV-2, and tuberculosis. They are adopting a multi-program and multi-platform approach to develop successful candidates in order to tackle antibiotic resistance. Manufacturers are innovating in antibody platforms and T cell platforms to isolate rare antibodies and use them to boost the immune system.
State-of-art DAAs Holds Promising Potentials for RSV Treatment
The respiratory syncytial virus (RSV) is being associated with limited treatment options, resulting in millions of hospitalizations per year. Palivizumab, a monoclonal antibody, is considered as the gold standard for prophylaxis in high-risk infants. However, palivizumab and ribavirin are prone to limited efficacy and significant safety concerns. Hence, manufacturers in the respiratory virus infection drugs market are increasing their research in direct acting antiviral agents (DAAs) to target key steps in the viral life cycle.
It has been found that DAAs are producing landmark clinical studies, which involve nucleoside inhibitors. On the other hand, non-nucleoside inhibitors of replication are being reviewed in addition to inhibitors of other mechanisms. As such, pharma companies in the respiratory virus infection drugs market are taking giant strides in R&D pertaining to viral proteins or host cell factors for inhibition of viral replication.
Companies Forge Strategic Partnerships to Innovate in Treatment for LRTI in Infants
In vitro and in vivo model systems of the RSV disease are being highlighted in order to create novel drug targets. Companies in the respiratory virus infection drugs market are expanding their treatment options for lower respiratory tract infections (LRTI). For instance, Sanofi— a global biopharmaceutical company, announced that it received positive Phase 2b trial for nirsevimab, since it showed significant decline in medically attended lower respiratory tract infections. This involves increased hospitalization caused due to RSV in healthy preterm infants.
Single dose monoclonal antibodies are found to significantly reduce medically attended RSV LRTI infants through the full RSV season. Nirsevimad is being highly publicized as an extended half-life RSV monoclonal antibody. Companies are entering into strategic partnerships to innovate in treatments for LRTI in infants. Nirsevimab is gaining popularity as the new standard of care by offering innovative immunization for immediate and sustained protection for all infants during the first season of RSV.
Expanding operations in future? To get the perfect launch ask for a custom report
Favipiravir and Boloxavir Approved for Influenza Treatment in Japan
Companies in the respiratory virus infection drugs market are increasing their production capabilities for anti-influenza drugs. Pharma companies in the respiratory virus infection drugs market are developing inhibitors of influenza virus polymerase, which are among the most promising types of drugs. Favipiravir and boloxavir are being approved for influenza treatment in Japan and the U.S. It has been found that favipiravir effectively and selectively inhibits the RNA dependent RNA polymerase of RNA viruses.
Sustainable pharmaceutical innovations in COVID-19 treatment hold promising potentials for other infectious diseases. Thus, the respiratory virus infection drugs market is estimated to grow at a healthy CAGR of ~7% during the assessment period. However, the issue of drug resistance in case of constant mutation of influenza virus is impacting market growth. Hence, pharma companies should conduct a sustained surveillance of the drug susceptibility of influenza viruses. Moreover, limited efficacy of influenza vaccines and drug resistance from small molecule antiviral drugs have led to the demand for new antivirals with novel mode of action.
Respiratory Virus Infection Drugs Market: Overview
- According to Transparency Market Research’s latest report on the global respiratory virus infection drugs market for the historical period 2018–2019 and forecast period of 2020–2030, increase in focus on research & development is projected to drive the global respiratory virus infection drugs market
- According to the report, the global respiratory virus infection drugs market was valued over US$ 38.6 Bn in 2019 and is anticipated to expand at a CAGR of ~7% from 2020 to 2030
- Respiratory virus infection is a type of infection of the airway and lungs caused by different types of virus. Viral respiratory infections (VRIs) include cold, flu, and bronchiolitis. Several medications are used for the treatment of respiratory virus infections including prescription and OTC.
Surge in Adoption of Combination Therapy to Drive Respiratory Virus Infection Drugs Market
- Adoption of combination therapy is increasing, as it is more effective than the separate use of bronchodilator and corticosteroid. Moreover, the number of patients being successfully treated with combination therapy has increased.
- Regulatory authorities such as the FDA, the European Commission, and the Ministry of Health, Labor and Welfare (MHLW) have approved the use of combination drugs for the treatment of respiratory diseases such as asthma and COPD
- Steady rise in prevalence of respiratory virus infections across the globe leads to high demand for advanced therapeutics. This, in turn, is expected to propel the global respiratory virus infection drugs market.
Increase in Expenditure on Healthcare and Immunization Augments Respiratory Virus Infection Drugs Market
- Rise in healthcare expenditure increases the availability of better healthcare infrastructure, improves operational efficiency, and encourages awareness programs related to vaccination and treatment of diseases
- According to the World Health Organization, expenditure on immunization in 72 countries across the globe increased between 2005 and 2015. According to the National Health Expenditure Accounts (NHEA), healthcare expenditure in the U.S. in 2017 was 17.9% of the GDP.
Patent Expiry of Branded Products and Availability of Generic Equivalents to Hamper Global Market
- Patents prevent other manufacturers from developing drugs that are being exclusively manufactured by the patent holder. Patent expiry of branded drugs has a significant impact on the pharmaceutical industry. It hampers the revenue generated from the sale of branded drugs and can affect the market share of a company. This, in turn, is likely to hamper the growth of the global respiratory virus infection drugs market.
- For instance, AstraZeneca’s Symbicort Turbuhaler went off-patent in Europe in 2019, whereas, GlaxoSmithKline plc’s Qvar, Singulair, and Diskus device patents have expired. This is projected to lead to dramatic decline in sales, thereby affecting market positions of the companies.
Respiratory Virus Infection Drugs Market: Competition Landscape
- This report profiles major players operating in the global respiratory virus infection drugs market based on various attributes and recent developments
- The global respiratory virus infection drugs market is highly fragmented, with the presence of large number of global as well as regional players
- Leading players operating in the global respiratory virus infection drugs market include
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sanofi, Cipla, Inc.
- CHIESI Farmaceutici S.p.A.
- Orion Corporation
Respiratory Virus Infection Drugs Treatment Market: Key Developments
- Leading players in the global respiratory virus infection drugs market engage in regulatory approvals, development of technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are aimed at addressing unmet needs in the global respiratory virus infection drugs market, strengthening the product portfolio and investments in research & development. A few expansion strategies adopted by players in the global respiratory virus infection drugs market are:
- In May 2019, Merck & Co., Inc. announced plans to invest US$ 1 Bn in its manufacturing facility in Elkton, Virginia, the U.S.
- In September 2018, AstraZeneca and its partner Amgen, Inc. (Amgen) announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation for tezepelumab for the treatment of severe asthma patients without an eosinophilic phenotype. This breakthrough therapy enabled the company to enhance its respiratory portfolio and treat a diverse population having severe asthma, including those ineligible for currently approved biologic therapies.
- In March 2018, Boehringer Ingelheim International GmbH announced that the indication for use of SPIRIVA Respimat (tiotropium Respimat) was extended. Regulatory authorities of the EU had accepted the add-on bronchodilator treatment therapy in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the past year.
- The report on the global respiratory virus infection drugs market discussed individual strategies, followed by company profiles of manufacturers of respiratory virus infection drugs products
- The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global respiratory virus infection drugs market
Respiratory Virus Infection Drugs Market – Scope of the Report
TMR’s report on the global respiratory virus infection drugs market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory virus infection drugs market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global respiratory virus infection drugs market during the forecast period.
The report has been prepared after primary and secondary researches. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global respiratory virus infection drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global respiratory virus infection drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global respiratory virus infection drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global respiratory virus infection drugs market.
The report delves into the competition landscape of the global respiratory virus infection drugs market. Key players operating in the global respiratory virus infection drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global respiratory virus infection drugs market that have been profiled in this report.
Key Questions Answered in Respiratory Virus Infection Drugs Market Report
- What is the scope of growth for product companies in the global respiratory virus infection drugs market?
- What will be the Y-o-Y growth of the global respiratory virus infection drugs market between 2020 and 2030?
- What is the influence of changing trends in technologies on the global respiratory virus infection drugs market?
- Will North America continue to be the most profitable market for respiratory virus infection drugs?
- Which factors are anticipated to hamper the global respiratory virus infection drugs market during the forecast period?
- Which are the leading companies in the global respiratory virus infection drugs market?
A unique methodology has been utilized by TMR to conduct comprehensive research on the growth of the global respiratory virus infection drugs market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary research sources referred to by analysts during the production of the global respiratory virus infection drugs market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the respiratory virus infection drugs market as primary methods.
These primary research respondents have provided exclusive information during interviews, which serves as a validation from the respiratory virus infection drugs market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global respiratory virus infection drugs market with accuracy. The study also uses the top-down approach to assess the revenues of each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global respiratory virus infection drugs more reliably and accurately.
Respiratory Virus Infection Drugs Market – Segmentation
Route of Administration
Mode of Purchase